InspireMD lifts COO Barry to the corner office InspireMD (OTC:NSPR) said yesterday it promoted COO Dr. James Barry to the office of CEO and president, effectively immediately. Former CEO Alan Milinazzo announced he would step down from the position in January. “We are extremely pleased to name Dr. Barry as President and CEO. Jim brings an […]
AliveCor said it plans to integrate its smartphone heart monitor with an electronic medical record platform for the 1st time.
MASSDEVICE ON CALL — Due to incorrect filings, the Dept. of Health & Human Services may have paid out as much as $1.5 billion too much in payments to nursing homes in 2009, according to an investigation by the inspector general.
MASSDEVICE ON CALL — Physicians may be relying too heavily on drug-eluting stents for patients who aren’t at significant risk of restenosis, a preference that could represent an unnecessary financial burden on the healthcare system, a new study suggests.
Opting for less expensive bare-metal stents for patients whose blood vessels aren’t at high risk of re-narrowing could save hundreds of millions of dollars per year without significantly increasing patients’ risk of requiring a repeat procedure, according to a retrospective study of the National Cardiovascular Data Registry CathPCI .
San Francisco-based startup Practice Fusion raised $34 million in its latest Series C funding round in support of its free online electronic medical record service, which the company says represents the largest physician-patient community in the U.S.
Carticept Medical closed a $10 million financing led by existing investors Domain Associates, New Enterprise Associates and SonoSite Inc.
The Alpharetta, Ga.-based company said it will use the proceeds to fund the commercial launch of its Navigator computer-controlled drug delivery system. The device uses ultrasound guidance to deliver medications for joint pain.
Lumbar spine surgery company TranS1 Inc. (NSDQ:TSON) priced a public offering of 6.2 million shares of common stock at $3.25 per share, expecting to raise up to $20.2 million.
TranS1 plans to use the funds for additional clinical trials, reimbursement efforts, sales personnel, research and product development activities and working capital, according to SEC filings. It added that funds may go toward acquisition of or investment in technologies, products or assets that complement the business.